Kraig Biocraft Laboratories Introduces New, Enhanced Line of Dragon Silk™ Silkworms for Commercial Production
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) has announced the successful development of new hybrid Dragon SilkTM silkworms aimed at enhancing large-scale production in Vietnam. These new breeds are designed to produce larger cocoons and longer silk filaments, which will significantly lower production costs and improve throughput. This initiative builds on the company's hybridization program initiated in 2018, resulting in silk cocoons that are 30-100% larger than traditional non-hybrid silkworms, thus facilitating a more consistent production platform.
- Development of new hybrid Dragon Silk silkworms enhances production efficiency.
- Larger cocoons and longer silk filaments are expected to reduce production costs.
- New breeds deliver 30-100% larger silk cocoons than non-hybridized silkworms.
- Successful transition to larger Dragon Silk line driven by demand increase.
- None.
ANN ARBOR, Mich., July 06, 2022 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces that it has produced several new lines of larger hybrid Dragon SilkTM silkworms for its production operations in Vietnam. These new breeds of silkworms were explicitly created for large-scale production.
With a larger cocoon and longer silk filament, these optimized Dragon Silk breeds reduce production costs and increase throughput.
The new breeds were created using a process of hybridization, combining the best properties of Dragon Silk with the best practices in silkworm breeding to improve the size and robustness of the silkworm strain. Commonly used in commercial mundane silk production, the process of creating these production hybrid silkworms delivers between 30
The Company first began the development of large cocoon hybrids in 2018. The success of that effort is the foundation of today's announcement and the rollout of this technology into production. Commercializing this technology required the Company to develop multiple strains of Dragon Silk hybrids that, when paired together, deliver a consistent and scalable large cocoon production platform.
"The hybridization program was a key part of the Company's technology roadmap and something our R&D team has been quietly working on behind the scenes," said Company COO Jon Rice. "Today, we announce that this technology is in the factory. This technology will lower our operating costs from rearing all the way through silk reeling and spinning. Over the coming months, our production team will transition egg production to this new, larger Dragon Silk line."
Accelerating the transition of these new larger breeds of Dragon Silk to production was driven by the Company's success with 3rd party contract production and our rapidly growing demand for increased quantities of Dragon Silk.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
